Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Operations: 2019-2025

Historic Cash from Operations for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to -$156.2 million.

  • Avidity Biosciences' Cash from Operations fell 138.01% to -$156.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$580.5 million, marking a year-over-year decrease of 214.66%. This contributed to the annual value of -$300.9 million for FY2024, which is 152.70% down from last year.
  • Per Avidity Biosciences' latest filing, its Cash from Operations stood at -$156.2 million for Q3 2025, which was up 21.78% from -$199.7 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Cash from Operations ranged from a high of $16.5 million in Q4 2023 and a low of -$199.7 million during Q2 2025.
  • Its 3-year average for Cash from Operations is -$81.9 million, with a median of -$65.6 million in 2024.
  • Per our database at Business Quant, Avidity Biosciences' Cash from Operations surged by 142.11% in 2023 and then plummeted by 705.24% in 2024.
  • Quarterly analysis of 5 years shows Avidity Biosciences' Cash from Operations stood at -$26.2 million in 2021, then tumbled by 49.49% to -$39.2 million in 2022, then spiked by 142.11% to $16.5 million in 2023, then tumbled by 705.24% to -$99.9 million in 2024, then plummeted by 138.01% to -$156.2 million in 2025.
  • Its Cash from Operations stands at -$156.2 million for Q3 2025, versus -$199.7 million for Q2 2025 and -$124.8 million for Q1 2025.